Women's Health

Arif Kamal, MD, MBA, MHS, chief patient officer at American Cancer Society, spoke with Healio about two national roundtables the society will launch to drive progress against breast cancer and cervical cancer.

Rucaparib monotherapy significantly extended PFS compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to topline data from the randomized phase 3 ATHENA-MONO trial.

Women who were employed in rotating or night shift work at some point in their lives are more likely to experience delayed onset of menopause compared with women working only during the day, according to study data published in Menopause.

Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results.

Current evidence does not support dehydroepiandrosterone use to improve women’s menopausal symptoms, sexual health and overall well-being, and long-term use may lead to estrogenic adverse events, according to a review article.

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

Black women undergoing treatment for gynecologic cancer reported significantly higher levels of race-associated stress compared with white women, according to study results.

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Women diagnosed with breast or gynecologic cancers underutilized both assisted reproductive technology and fertility-sparing oncology care, according to study results.

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.